Neuroendocrine Prostate Cancer

Oncology

Prevalence

143.5 / 100K

Incidence

18.4 / 100K/yr

19 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
[177Lu]Lu-DOTA-TATE	Novartis AG (NVS)
gonadotropin-releasing hormone analogues	NOVARTIS AG (NVSEF)

Phase 1(14)

Drug	Company
[177lu]lu-dota-tate	Novartis AG (NVS)
[177lu]lu-neob	Novartis AG (NVS)
[177lu]lu-psma-617	Novartis AG (NVS)
[177Lu]Lu-PSMA-617	Novartis AG (NVS)
[68ga]ga-dota-tate	Novartis AG (NVS)
[68ga]ga-neob	Novartis AG (NVS)
[68ga]ga-psma-11	Novartis AG (NVS)
[68ga]ga-psma-11	Novartis AG (NVS)
177lu-dfc413	Novartis AG (NVS)
antiemetics & antinauseants	NOVARTIS AG (NVSEF)
antiemetics & antinauseants	Novartis AG (NVS)
gnrh antagonists	Novartis AG (NVS)
gnrh antagonists	NOVARTIS AG (NVSEF)
gonadotropin-releasing hormone analogues	Novartis AG (NVS)

Phase 1/Phase 2(3)

BioSniper tracks 19 drugs in development for Neuroendocrine Prostate Cancer across 2 companies.

There are 1 clinical trial targeting Neuroendocrine Prostate Cancer tracked by BioSniper.

The estimated prevalence of Neuroendocrine Prostate Cancer is approximately 143.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.